Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.

Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.

Item
http://www.wikidata.org/entity/Q30397897
Influenza vaccination in HIV-positive subjects: latest evidence and future perspectiveInfluenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspectiveSeroconversion of 2009 pandemic influenza A (H1N1) vaccination in kidney transplant patients and the influence of different risk factors.High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients.Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults.Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients.Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults.Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controlsHigher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.Immune response to 2009 H1N1 vaccine in HIV-infected adults in Northern Thailand.Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals.Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohortVitamin D Levels, Natural H1N1 Infection and Response to H1N1 Vaccine among HIV-Infected IndividualsImmune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls.The Comparison of Sensitivity and Specificity of ELISA-based Microneutralization Test with Hemagglutination Inhibition Test to Evaluate Neutralizing Antibody against Influenza Virus (H1N1).
P2860

Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.

Item
http://www.wikidata.org/entity/Q30397897
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@ast
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@en
type
label
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@ast
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@en
prefLabel
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@ast
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@en
P2093
P304
P31
P356
10.1016/J.VACCINE.2010.12.023
P407
P433
P478
P577
P698
P921